Shares of Intellia Therapeutics fell after the company reported a grade 4 adverse event in a study of nex-z, its treatment for hereditary ATTR amyloidosis with polyneuropathy. The stock was down 24% ...

Intellia reports a grade 4 liver enzyme elevation in a Nex-Z trial patient; no hospitalization is required, and enrollment ...

CM, offers strong efficacy and a favorable safety profile compared to competitors. See why I rate ALNY stock a Hold.

Intellia Therapeutics (NASDAQ:NTLA) shares tumbled in the premarket on Thursday after the biotech disclosed that a patient ...

Intellia Therapeutics (NASDAQ:NTLA) saw its stock tumble by 19% after releasing a safety update related to its Phase 3 ...

Oppenheimer downgraded Prothena Corporation plc (NASDAQ:PRTA) to Perform from Outperform on May 27 without a price target.

Despite scientific advances in cardiovascular care, people living in rural areas and other communities with long-term ...

Safety and efficacy of four drug regimens in newly diagnosed multiple myeloma: Systematic review. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does not include a ...

A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. Privately held City Therapeutics is getting $46 million in the deal. That ...

Prothena Corporation (NASDAQ:PRTA) is a clinical-stage neuroscience company that discovers and develops novel therapies for ...

Prothena (PRTA) stock drops as a late-stage trial for the company's lead candidate fails, prompting Oppenheimer and Jefferies ...

Prothena has made the decision to discontinue the AFFIRM-AL trial, including the open-label extension portion.